Mechanism of antiviral activities of 3′-substituted L-nucleosides against 3TC-resistant HBV polymerase: A molecular modelling approach

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 6, 2003, Pages 309-319

  Chong, Youhoon ^a   Stuyver, Lieven ^b   Otto, Michael J ^b   Schinazi, Raymond F ^b,c   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b PHARMASSET INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3TC; HBV; Hepatitis B; HIV; L nucleosides; Reverse transcriptase

Indexed keywords

3' FLUORO 2',3' DIDEOXYCYTIDINE; AMIDE; AZIDE; CLEVUDINE; DNA POLYMERASE; FLUORINE DERIVATIVE; LAMIVUDINE; METHIONINE; NUCLEOSIDE; RIBOSE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VALINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; ATOM; CHEMICAL BOND; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN STABILITY; PROTEIN STRUCTURE; STEREOCHEMISTRY; VIRUS RESISTANCE;

EID: 0842327503     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400603     Document Type: Article

References (48)

1. Afdhal NH, O'Brien CB, Oshana SC & Dunkle LM (2002) Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: predictions for activity against YMDD mutant strains. Hepatology 36:4 (Part 2 of 2).
2. Allen MI, Deslauriers M Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N & Condreay LD (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
3. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condrea LD, Tzakis AG, Schiff ER & Brown NA (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
4. Birnbaum GI, Giziewicz J, Gabe EJ, Lin TS & Prusoff WH (1987) Structure and conformation of 3′-azido-3′-deoxythymidine (AZT), an inhibitor of the HIV (AIDS) virus. Canadian Journal of Chemistry 65:2135-2139.
5. Birnbaum GI, Lin TS & Prusoff WH (1988) Unusual structural features of 2′,3′-dideoxycytidine, an inhibitor of the HIV (AIDS) virus. Biochemical & Biophysical Research Communications 151:608-614.
6. Blaney JM, Weiner PK, Dearing A, Kollman PA, Jorgensen EC, Oatley SJ, Burridge JM & Blake CCF (1982) Molecular mechanics simulation of protein ligand interactions. Binding of thyroid-hormone analogs to pre-albumin. Journal of the American Chemical Society 104:6424-6434.
7. Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach J-L, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Marion P, Cretton-Scott E, Schinazi RF & Sommadossi J-P (2001) Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrobial Agents & Chemotherapy 45:229-235.
8. Bryant ML, Gosselin G, Schinazi RF, Imbach J-L & Sommadossi J-P (2000) Anti-hepatitis B specific β-L-2′-deoxynucleosides. Antiviral Research 46:A55-A55.
9. Chong Y & Chu CK (2002) Understanding the unique mechanism of CLV (Clevudine) against hepatitis B virus: Molecular dynamics studies. Bioorganic & Medicinal Chemistry Letters 12:3459-3462.
10. Chong Y, Borroto-Esoda K, Furman PA, Schinazi RH & Chu CK (2002) Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine-drug resistant mutants: a molecular modeling approach. Antiviral Chemistry & Chemotherapy 13:115-128.
11. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, Gerin JL, Cote PJ, Tennant BC & Cheng YC (1998) Preclinical investigation of CLV as an anti-hepatitis B virus agent. Antiviral Therapy 3:113-121.
12. Chu CK, Ma TW, Shanhmuganathan K, Wang CG, Xiang YJ, Pai SB, Yao GQ, Sommadossi J-P & Cheng YC (1995) Use of 2′ -fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis-B virus and Epstein-Barr-virus. Antimicrobial Agents & Chemotherapy 39:979-981.
13. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW & Kollman PA (1995) A 2nd generation force-field for the simulation of proteins, nucleic acids, and organic-molecules. Journal of the American Chemical Society 117:5179-5197.
14. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG & Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 75:4771-4779.
15. Delaney WE, Locarnini S & Shaw T (2001) Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chemistry & Chemotherapy 12:41-75.
16. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M & Brown NA (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 341:1256-1263.
17. Dunitz JD & Taylor R (1997) Organic fluorine hardly ever accepts hydrogen bonds. Chemistry-A European Journal 3:89-98.
18. Faraj A, El Alaoui MA, Pavia G, Gosselin G, Imbach J-L, Schinazi RH & Sommadossi J-P (1997) Antiviral activities of beta-enantiomers of 3′-substituted-3′-deoxythymidine analogs. Nucleosides & Nucleotides 16:1287-1290.
19. Gästeiger J & Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228.
20. Graciet JCG & Schinazi RH (1999) From D- to L-nucleoside analogs as antiviral agents. Advances in Antiviral Drug Design 3:1-68.
21. Gumina G, Schinazi RH & Chu CK (2001) Synthesis and potent anti-HIV activity of L-3′-fluoro-2′,3′-unsaturated cytidine. Organic Letters 3:4177-4180.
22. Gumina G, Song GY & Chu CK (2001) L-nucleosides as chemotherapeutic agents. FEMS Microbiology Letters 202:9-15.
23. Hoofnagle JH & di Bisceglie AM (1997) The treatment of chronic viral hepatitis. New England Journal of Medicine 336:347-356.
24. Huang H, Chopra R, Verdine GL & Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
25. Jarvis B & Faulds D. (1999) Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 58:101-141.
26. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL & Gray DF (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine 339:61-68.
27. Lai CL, Myers MW, Pow DM, Brown NA, Lee YM, Yuen MF & Lim SG (2001) Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): results of a dose-escalation trial. Hepatology 34:321A.
28. Lee K & Chu CK (2001) Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrobial Agents & Chemotherapy 45:138-144.
29. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180.
30. Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE & Cheng YC (1994) Antiviral activity of 2′,3′-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2′,3′-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis-B virus and human-immunodeficiency-virus type-1 in vitro. Biochemical Pharmacology 47:171-174.
31. Lin TS, Luo MA, Liu MC, Zhu YL, Gullen E, Dutschman GE & Cheng YC. (1996) Design and synthesis of 2′,3′-dideoxy-2′,3′ -didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy-2′ ,3′-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39:1757-1759
32. Maga G, Amacker M, Hübscher U, Gosselin G, Imbach J-L, Mathé C, Faraj A, Sommadossi J-P & Spadari S (1999) Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3′-hydroxyl group of the L-β-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs. Nucleic Acids Research 27:972-978.
33. Miller RH, Kaneko S, Chung CT, Girones R & Purcell RH (1989) Compact organization of the hepatitis B virus genome. Hepatology 9:322-327.
34. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ & Murray A (1999) Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. Journal of Clinical Investigation 103:1635-1640.
35. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P & Murray A (2000) Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
36. Purcell WP & Singer JA (1967) A brief review and table of semiempirical parameters used in Hückel molecular orbital method. Journal of Chemical & Engineering Data 12:235-246.
37. Schinazi RH, Schlueter-Wirtz S & Stuyver L (2001) Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antiviral Chemistry & Chemotherapy 12 (Suppl 1):61-65.
38. Seta T, Yokosuka O, Imazeki F, Tagewa M & Saisho H (2000) Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. Journal of Medical Virology 60:8-16.
39. Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Grier J, Tharnish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ & Schinazi RH (2002) Antiviral activities and cellular toxicities of modified 2′,3′ -dideoxy-2′,3′-didehydrocytidine analogues. Antimicrobial Agents & Chemotherapy 46:3854-3860.
40. Tiollais P, Pourcel C & Dejean A (1985) The hepatitis B virus. Nature 317:489-495.
41. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM & Tyrrell DL (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
42. Van roey P, Pangborn WA, Schinazi RH, Painter G & Liotta DC (1993) Absolute-configuration of the antiviral agent (-)-cis-5-fluoro-1-[2-hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antiviral Chemistry & Chemotherapy 4:369-375.
43. Van roey P, Taylor EW, Chu CK & Schinazi RH (1993) Conformational-analysis of 2′,3′-didehydro-2′,3′ -dideoxypyrimidine nucleosides. Journal of the American Chemical Society 115:5365-5371.
44. Wang P, Hong JH, Cooperwood JS & Chu CK (1998) Recent advances in L-nucleosides: chemistry and biology. Antiviral Research 40:19-44.
45. Weiner SJ, Kollman PA, Nguyen DT & Case DA (1986) An all atom force-field for simulations of proteins and nucleic-acids. Journal of Computational Chemistry 7:230-252.
46. Wipff G, Dearing A, Weiner PK, Blaney JM & Kollman PA (1983) Molecular mechanics studies of enzyme-substrate interactions - The interaction of L-N-acetylryptophanamide and D-N-acetyl-tryptophanamide with α-chymotrypsin. Journal of the American Chemical Society 105:997-1005.
47. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS & Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 119:312-323.
48. Yeh CT, Chien RN, Chu CM & Liaw YF (2000) Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.